Transfer of Pathogenic IgG from Long COVID Patients with Neurological Symptoms Induces Sensitivity Without Affecting Cognitive Function in Mice - Scorecard - MDSpire
Advertisement
Transfer of Pathogenic IgG from Long COVID Patients with Neurological Symptoms Induces Sensitivity Without Affecting Cognitive Function in Mice
Clinical Scorecard: Transfer of Pathogenic IgG from Long COVID Patients with Neurological Symptoms Induces Sensitivity Without Affecting Cognitive Function in Mice
At a Glance
Category
Detail
Condition
Long COVID with neurological symptoms including cognitive impairment and neuropathic pain
Key Mechanisms
Potential autoimmunity mediated by pathogenic IgG antibodies targeting nervous system epitopes
Target Population
Adults with prior SARS-CoV-2 infection experiencing persistent neurological symptoms for at least 2 months
Care Setting
Post-acute COVID-19 outpatient clinical evaluation and research settings
Key Highlights
Approximately 10% of COVID-19 patients develop long COVID with persistent symptoms including cognitive impairment and neuropathic pain.
Autoantibodies targeting nervous system antigens have been detected in some long COVID patients with neurological symptoms, suggesting immune dysregulation.
Passive transfer of purified IgG from long COVID patients to mice induced pain sensitivity but did not affect cognitive or affective behaviors.
Guideline-Based Recommendations
Diagnosis
Use WHO 2021 consensus definition for long COVID diagnosis: symptoms persisting at least 2-3 months post SARS-CoV-2 infection.
Exclude alternative diagnoses including chronic pain, neurodegenerative diseases, autoimmune diseases, and other infections (e.g., CMV, EBV).
Perform neuropsychological assessments (e.g., MoCA, SDMT) and neuroimaging as clinically indicated.
Management
Currently no validated treatments for long COVID neurological symptoms; therapeutic plasmapheresis shows potential benefit by reducing autoantibody levels.
Symptomatic management of pain and cognitive symptoms as per standard clinical practice.
Monitoring & Follow-up
Regular clinical follow-up to assess symptom progression or remission.
Monitor autoantibody levels if clinically relevant and available.
Neuropsychological testing to track cognitive function over time.
Risks
Potential development of new-onset autoimmune diseases post COVID-19.
Neuropathic pain and cognitive impairment may significantly impact quality of life.
Patient & Prescribing Data
Adults with long COVID exhibiting neurological symptoms including cognitive impairment and neuropathic pain.
No specific pharmacological treatments validated; immunomodulatory approaches such as plasmapheresis may reduce autoantibody levels and improve symptoms.
Clinical Best Practices
Thorough clinical assessment including detailed history of SARS-CoV-2 infection and symptomatology.
Exclude other causes of neurological symptoms through laboratory tests and imaging.
Use standardized neuropsychological tests for cognitive evaluation.
Consider research protocols for passive transfer studies to understand pathogenic mechanisms.
Monitor patients longitudinally for symptom evolution and potential autoimmune sequelae.
by Margaux Mignolet, Catherine Deroux, Thomas Florkin, Valéry Bielarz, Kathleen De Swert, Nicolas Halloin, Lindsay Sprimont, Aurélie Ladang, Fabienne George, Jacques Gilloteaux, Laurence Abeloos, Pierre Garin, Johan Van Weyenbergh, Marc Jamoulle, Claire Diederich, Nicolas Albert Gillet, Pierre Bulpa, Charles Nicaise
